entresto 50 mg
novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril - entresto is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entresto has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy
entresto 50 mg
novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy
entresto 50 mg
novartis israel ltd - sacubitril/valsartan as sodium salt complex - film coated tablets - sacubitril/valsartan as sodium salt complex 24/26 mg - valsartan and sacubitril - entrestotm is indicated for the treatment of heart failure (nyha class ii-iv) in patients with systolic dysfunction. entrestotm has been shown to reduce the rate of cardiovascular death and heart failure hospitalisation compared to angiotensin converting enzyme (ace) inhibitor therapy
simulect for injection 20 mgvial
novartis (singapore) pte ltd - basiliximab - injection, powder, for solution - 20 mg/vial - basiliximab 20 mg/vial
ciproxin hc ear drops 0.2% ciprofloxacin (as hydrochloride) and 1% hydrocortisone ear drops
novartis pharmaceuticals australia pty ltd - ciprofloxacin, quantity: 2 mg/ml; hydrocortisone, quantity: 10 mg/ml - ear drops, suspension - excipient ingredients: polysorbate 20; sodium acetate; glacial acetic acid; benzyl alcohol; hydrogenated soy phosphatidylcholine; sodium chloride; polyvinyl alcohol; purified water - for the treatment of acute bacterial otitis externa, caused by organisms susceptible to ciprofloxacin (see pharmacology), in adults and children aged 2 years and older.
exjade
novartis pharma stein ag - deferasirox - tablets dispersible - 250mg
exjade
novartis pharma stein ag - deferasirox - tablets dispersible - 500mg
exforge hct 5mg/160mg/12.5mg tablets film-coated
novartis pharma stein ag - amlodipine (amlodipine besilate), valsartan, hydrochlorothiazide - tablets film-coated - 5mg+ 160mg+ 12,5mg
exforge hct 10mg/160mg/12.5mg tablets film-coated
novartis pharma stein ag - amlodipine (amlodipine besilate), valsartan, hydrochlorothiazide - tablets film-coated - 10mg+ 160mg+ 12,5mg
exforge hct 5mg/160mg/25mg tablets film-coated
novartis pharma stein ag - amlodipine (amlodipine besilate), valsartan, hydrochlorothiazide - tablets film-coated - 5mg+ 160mg+ 25mg